High glucose induces hippocampal neuron impairment through the SKP1/COX7C pathway: A potential mechanism for perimenopausal depression.
10.1016/j.apsb.2025.09.003
- Author:
Ziqi WANG
1
;
Zhiyuan LIU
1
;
Sijia FENG
1
;
Xintong SONG
1
;
Dequan LIU
1
;
Ning MA
1
;
Xinyue ZHANG
1
;
Weiwei LIU
1
;
Dan Ohtan WANG
1
;
Xiaoling LIU
1
;
Takashi IKEJIMA
1
Author Information
1. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Publication Type:Journal Article
- Keywords:
COX7C;
Depression;
Glucose;
Mitochondrion;
Neuron;
Perimenopause;
SKP1;
Ubiquitination
- From:
Acta Pharmaceutica Sinica B
2025;15(11):5832-5853
- CountryChina
- Language:English
-
Abstract:
Perimenopause raises the risk and incidence of depression, whereas the underlying molecular mechanism remains unclear. Disturbed glucose regulation has been widely documented in depressive disorders, which renders the brain susceptible to various stresses such as estrogen depletion. However, whether and how glucose dysfunction regulates depression-like behaviors and neuronal damage in perimenopausal transition remains unexplored. Here, a prominent depressive phenotype was found in perimenopausal mice induced by the ovarian toxin 4-vinylcyclohexene diepoxide (VCD). The VCD depression susceptible group (VCDSS) and the VCD depression resilient group (VCDRES) were determined using a ROC-based behavioral screening approach. We found that the hippocampus, a crucial region linked to depression, had hyperglycemia and mitochondrial abnormalities. Interestingly, oral administration of the SGLT2 inhibitor empagliflozin (EMPA) and intrahippocampal glucose infusion suggest a close relationship between hyperglycemia in the hippocampus and the susceptibility to depression. We verified that cytochrome c oxidase 7c (COX7C) downregulation is a potential cause of the high glucose-induced neuronal injury using proteomic screening and biochemical validations. High glucose causes COX7C to be ubiquitinated in a S-phase kinase associated protein 1 (SKP1)-dependent manner. According to these results, SKP1/COX7C represents a unique therapeutic target and a novel molecular route for treating perimenopausal depression.
